Study of extended spectrum β-lactamase producing Enterobacteriaceae and antibiotic coresistance in a tertiary care teaching hospital

Journal of Natural Science, Biology and Medicine

Volumn 5, Issue 1, 2014, Pages 30-35

  Shashwati, Nema ^a   Kiran, Tripathi ^a   Dhanvijay, A ^a  

^a JLN Medical College   (India)

Author keywords

Antibiotic coresistance; Enterobacteriaceae; extended spectrum lactamase

Indexed keywords

EID: 84897615353     PISSN: 09769668     EISSN: 22297707     Source Type: Journal    
DOI: 10.4103/0976-9668.127280     Document Type: Article

References (36)

1. Kotra LP, Samama J, Mobashery S. Beta-lactamases and their resistance to beta-lactam antibiotics. In: Lewis K, Salyers AA, Taber HW, Wax RG, editors. Bacterial resistance to antimicrobials. New York: Marcel Decker 2002. p. 123-60.
2. Samaha-Kfoury JN, Araj GF. Recent development in β-lactamases and extended spectrum β-lactamases. BMJ 2003;327:1209-13.
3. Brodford PA. Extended spectrum β-lactamases in the 21 st century. Characterization, epidemiology and detection of this important resistance threat. Clin Microbiol Rev 2001;14:933-51.
4. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β lactamases and its correlation with molecular structures. Antimicrob Agents Chemother 1995;39:1211-33.
5. Paterson DL, Bonomo RA. Extended spectrum β-lactamases; a clinical update. Clin Microbiol Rev 2005;18:657-86.
6. Luzzaro F, Mezzatesta M, Mugnaioli C, Perilli M, Stefani S, Amicosante G, et al. Extended-spectrum β-lactamases among enterobacteria of Medical interest: Report of the second Italian Nationwide survey. J Clin Microbiol 2006;44:1659-64.
7. Jacoby GA. Extended spectrum beta-lactamases and other enzymes providing resistance to oxyimino-beta lactams. Infect Dis Clin North Am 1997;11:875-87.
8. Thomson KS, Prevan AM, Lagrange PH. Novel plasmid mediated beta-lactamases in Enterobacteriaceae: Emerging problems for new beta-lactam antibiotics. Curr Clin Topics Infect Dis 1996;16:151-63.
9. Jacoby GA, Sutton L. Properties of plasmids responsible for production of extended spectrum beta lactamases. Antimicrob Agents Chemother 1991;35:164-9.
10. Das N, Borthakur AK. Antibiotic coresistance among extended-spectrum beta lactamase-producing urinary isolates in a tertiary medical center: A prospective study. Chron Young Sci 2012;1:53-6.
11. Rudresh SM, Nagarathnamma T. Extended spectrum β-lactamase producing Enterobacteriaceae and antibiotic co-resistance. Indian J Med Res 2011;133:116-8.
12. Umadevi S, Kandhakumari G, Joseph NM, Kumar S, Easow JM, Stephen S, et al. Prevalence and antimicrobial susceptibility pattern of ESBL producing Gram Negative Bacilli. J Clin Diagn Res 2011;5:236-9.
13. Metri Basavaraj C, Jyothi P, Peerapur Basavaraj V. The prevalence of ESBL among Enterobacteriaceae in a tertiary care hospital of North Karnataka, India. J Clin Diagn Res 2011;5:470-5.
14. Khan MK, Thukral SS, Gaind R. Evaluation of a modified double disc synergy test for detection of extended spectrum β-lactamases in AmpC β-lactamase producing proteus mirabilis. Indian J Med Microbiol 2008;26:58-61.
15. Kumar MS, Lakshmi V, Rajagopalan R. Occurrence of extended spectrum beta-lactamases among Enterobacteriaceae spp. isolated at a tertiary care institute. Indian J Med Microbiol 2006;24:208-11.
16. Rodrigues C, Joshi P, Jani SH, Alphonse M, Radhakrishnan R, Mehta A. Detection of β-Lactamases in nosocomial Gram negative clinical isolates. Indian J Med Microbiol 2004;22:247-250.
17. Win WC, Allen SD, Janda WM, Koneman EW, Procop GW, Schreckenberger PC, Woods G, editors. Colour atlas and text book of diagnostic microbiology. 6 th ed. Philadelphia: Lippincott Williams and Wilkins; Enterobacteriaceae; 2006. p. 211-302.
18. Bauer AW, Kirby WM, Sherris JC, Jurck M. Antibiotic susceptibility testing by a Standardized Single disc diffusion method. Am J Clin Pathol 1996;45:493-6.
19. Clinical and Laboratory Standard Institute. Performance Standards for Antimicrobial Susceptibility Testing; 21 st Informational Supplement. CLSI document Jan 2011;M100-S21;Vol 31 No. 1. Supplemental [Table 2]A-S1.p. 48-9.
20. Mohamudha PR, Harish BN, Parija SC. Amp C beta lactamases among gram negative clinical isolates from a tertiary hospital, South India. Braz J Microbiol 2010;41:596-602.
21. Polsfuss S, Bloemberg GV, Giger J, Meyer V, Bottger EC, Hambach M. Practical approach for reliable detection of AmpC beta-lactamases producing Enterobacteriaceae. J Clin Microbiol 2011;49:2798-803.
22. Eisentein BI, Zaleznik DF. Enterobacteriaceae. In: Mandell GL, Bennett JE Dolin R, editors. Principles and practice of infectious diseases. 5 th ed. Philadelphia, Pa: Churchill Living Stone; 2000. p. 2294-310.
23. Komatsu M, Ikeda N, Aihara M, Nakamachi Y, Kinoshita S, Yamasaki K, et al. Hospital outbreak of MEN-1-derived extended spectrum beta-lactamase- producing Klebsiella pneumoniae. J Infect Chemother 2001;7:94-101.
24. Rice LB, Willey SH, Papanicolaou GA, Medeiros AA, Eliopoulos GM, Moellering RC Jr, et al. Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility. Antimicrob Agent Chemother 1990; 34:2193-9.
25. Wiener J, Quinn JP, Bradford PA, Goering RV, Nathan C, Bush K, et al. Multiple antibiotic resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999; 281:517-23.
26. Gavin PJ, Bolden JR Jr, Peterson LR, Thomson RB Jr. Does identification of an extended spectrum beta-lactamase (ESBL) producing organism by the microbiology laboratory influence patient management? Infect Dis Clin Pract 2006; 14:81-3
27. Gotale M, Manthalkar P, Kandle S, Yamul V, Jahagirdhar V. Co-relation of extended spectrum β-lactamase production with cephalosporins resistance in Gram negative bacilli. Indian J Pathol Microbiol 2004; 47:82-4.
28. Shah AA, Hasan F, Ahmed S, Hameed A. Extended Spectrum beta-lactamase in Enterobacteriaceae: Related to age and gender. New Microbiol 2002; 25:363-6.
29. Gupta E, Mohanty S, Sood S, Dhawan B, Das BK, Kapil A. Emerging resistance to carbapenems in a tertiary care hospital in north India. Indian J Med Res 2006; 124:95-8.
30. Moczygemba LR, Frei CR, Burgess DS. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases. Clin Ther 2004;26:1800-7.
31. Wong-Beinger A. Therapeutic challenges associated with extended-spectrum Beta-lactamases producing Escherichia coli and Klebsiella pneumoniae. Pharmacotherapy 2001;21:583-92.
32. Al-Zahrani AJ, Akhtar N. Susceptibility patterns of Extended Spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae isolated in a teaching hospital. Pakistan J Med Res 2005;44:64-7.
33. Bano JR, Navarro MD, Retamar P, Picon E, Pascual A. β-lactam/ βlactam inhibitor combinations for the treatment of bacteremia due to Extended-Spectrum β-lactamase-producing Escherichia coli: A post Hoc analysis of prospective cohort. Clin Infect Dis 2012;54:167-74.
34. Peterson LR. Antibiotic policy and prescribing strategies for therapy of extended-spectrum β-lactamase-producing Enterobacteriaceae: The role of piperacillin-tazobactam. Clin Microbiol Infect 2008;14:181-4.
35. Ullah F, Malik SA, Ahmed J. Antibiotic susceptibility pattern and ESBL prevalence in nosocomial Escherichia coli from urinary tract infections in Pakistan. Afr J Biotechnol 2009;8:3921-6.
36. Martínez-Martínez L, Pascual A, Conejo Mdel C, García I, Joyanes P, Doménech-Sánchez A, et al. Energy-dependent accumulation of norfloxacin and porin expression in clinical isolates of Klebsiella pneumoniae and relationship to extended-spectrum beta-lactamase production. Antimicrob Agents Chemother 2002; 46:3926-32.